

# Paul N Mainwaring

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11409778/publications.pdf>

Version: 2024-02-01

23  
papers

4,233  
citations

430874

18  
h-index

677142

22  
g-index

23  
all docs

23  
docs citations

23  
times ranked

5348  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015, 373, 1814-1823.	27.0	1,004
2	Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1408-1418.	27.0	947
3	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 917-927.	10.7	789
4	Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. <i>Lancet Oncology</i> , The, 2012, 13, 1210-1217.	10.7	254
5	Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial—FIRSTANA. <i>Journal of Clinical Oncology</i> , 2017, 35, 3189-3197.	1.6	251
6	Apalutamide and Overall Survival in Prostate Cancer. <i>European Urology</i> , 2021, 79, 150-158.	1.9	150
7	Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1193-1199.	10.7	142
8	Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1404-1416.	10.7	105
9	Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m <sup>2</sup> combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2009, 65, 192-197.	2.0	92
10	Merging new-age biomarkers and nanodiagnosics for precision prostate cancer management. <i>Nature Reviews Urology</i> , 2019, 16, 302-317.	3.8	86
11	Design and Clinical Verification of Surface-Enhanced Raman Spectroscopy Diagnostic Technology for Individual Cancer Risk Prediction. <i>ACS Nano</i> , 2018, 12, 8362-8371.	14.6	66
12	A digital single-molecule nanopillar SERS platform for predicting and monitoring immune toxicities in immunotherapy. <i>Nature Communications</i> , 2021, 12, 1087.	12.8	62
13	Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC. <i>Clinical Cancer Research</i> , 2010, 16, 2906-2914.	7.0	58
14	Toward Precision Medicine: A Cancer Molecular Subtyping Nanostrategy for RNA Biomarkers in Tumor and Urine. <i>Small</i> , 2016, 12, 6233-6242.	10.0	52
15	Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. <i>Lancet Oncology</i> , The, 2014, 15, 1263-1268.	10.7	46
16	Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 757-764.	1.6	43
17	Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5516-5516.	1.6	41
18	A simple, rapid, low-cost technique for naked-eye detection of urine-isolated TMPRSS2:ERG gene fusion RNA. <i>Scientific Reports</i> , 2016, 6, 30722.	3.3	21

#	ARTICLE	IF	CITATIONS
19	The role of circulating tumor DNA testing in breast cancer liquid biopsies: getting ready for prime time. <i>Breast Cancer Management</i> , 2020, 9, .	0.2	12
20	Phosphoprotein Biosensors for Monitoring Pathological Protein Structural Changes. <i>Trends in Biotechnology</i> , 2020, 38, 519-531.	9.3	8
21	Multidisciplinary consensus: A practical guide for the integration of abiraterone into clinical practice. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 228-236.	1.1	3
22	Phase II study of sequential first-line pazopanib (PAZ) followed by everolimus (EVE) in patients (pts) with advanced or metastatic renal cell carcinoma (RCC) (CATCHez Study).. <i>Journal of Clinical Oncology</i> , 2018, 36, 648-648.	1.6	1
23	Cancer Therapy: Toward Precision Medicine: A Cancer Molecular Subtyping Nano-Strategy for RNA Biomarkers in Tumor and Urine ( <i>Small</i> 45/2016). <i>Small</i> , 2016, 12, 6302-6302.	10.0	0